Adjuvant treatment (treatment after surgery to remove the pancreatic cancer) with the chemotherapy drug S-1 increased Overall Survival (OS) among Japanese patients according to results of a phase III trial presented at the ASCO Gastrointestinal Cancers Symposium in San Fransisco…
on 29th January 2013
Celgene UK and Ireland, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that its phase III clinical trial of ABRAXANE® (nab-paclitaxel) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with metastatic pancreatic cancer (who…
on 23rd January 2013
Pancreatic Cancer Action (PCA) is to fund researchers at the University of Cambridge to identify the key symptoms associated with pancreatic cancer in order to inform consumer awareness campaigns and underpin the development of general-practice-based interventions aimed at earlier diagnosis…
on 14th January 2013
[caption id="attachment_7412" align="alignright" width="300"] Joanna David, Patron of Pancreatic Cancer Action[/caption] Pancreatic Cancer Action is delighted to announce British actress Joanna David as a new patron. Joanna is one of the UK’s most cherished actresses and has been a familiar…
on 9th January 2013